- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
Transcript (slightly modified)
When a new reimbursement model is being developed, at what stage should providers become involved?
My goal is that we should be involved from day 1. I was in practice for almost 20 years before joining Aetna, and the last time that I spoke to a provider as on oncologist was when they were denying some type of care plan that I was requesting. So, this is a 360-degree change. We communicate and collaborate together. I feel that from a provider perspective and with our oncology medical home models, which parallel the oncology care model, we should work together on coming up with what the ideal payment plan is going to be, and that’s our goal.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
